Please enter a valid month/year e.g. 01/2015

Pick a date between March 2000 and February 2024

Showing 1 to 10 of 483
Title Type Expected publication date
Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897] Technology appraisal guidance Expected publication date:TBC 0
Abatacept for treating active psoriatic arthritis after DMARDs [ID993] Technology appraisal guidance Expected publication date:TBC 0
Abdominal aortic aneurysm: diagnosis and management NICE guideline Expected publication date:TBC 0
Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147 Technology appraisal guidance Expected publication date:TBC 0
Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy ID1347 Technology appraisal guidance Expected publication date:TBC 0
Abemaciclib with an aromatase inhibitor for untreated advanced hormone-receptor positive, HER2-negative breast cancer [ID1227] Technology appraisal guidance Expected publication date:27 February 2019 20190227
Abemaciclib with fulvestrant for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy ID1339 Technology appraisal guidance Expected publication date:20 March 2019 20190320
Abiraterone for the treatment of metastatic, castrate-resistant prostate cancer following previous cytotoxic chemotherapy TA259 Technology appraisal guidance Expected publication date:TBC 0
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945] Technology appraisal guidance Expected publication date:TBC 0
Acne Vulgaris: Management NICE guideline Expected publication date:13 January 2021 20210113